PMID- 17367819
OWN - NLM
STAT- MEDLINE
DCOM- 20070625
LR  - 20111117
IS  - 0024-3205 (Print)
IS  - 0024-3205 (Linking)
VI  - 80
IP  - 20
DP  - 2007 Apr 24
TI  - HLA-DRB1*04 gene polymorphisms and expressions profiles of interleukin-18 and 
      interleukin-18 binding protein following in vitro stimulation in human peripheral 
      blood mononuclear cells of healthy individuals and patients with rheumatoid 
      arthritis.
PG  - 1887-96
AB  - Rheumatoid arthritis (RA) is a chronic arthritic condition that can lead to 
      deformities and disabilities. Interleukin-18 (IL-18) is a proinflammatory 
      cytokine known to play a role in the acute and chronic inflammatory phases of RA. 
      IL-18 binding protein is the natural antagonist of IL-18 protein. We aim to 
      identify the effect of HLA-DRB1*04 gene polymorphisms on IL-18 and IL-18BP gene 
      expressions profiles as well as the time-course profiles following in vitro 
      stimulation with mitogens. Peripheral blood mononuclear cells from 16 RA patients 
      and 21 healthy controls were cultured for 1, 4, 8, 12, 24, 48 and 72 h following 
      stimulation with either LPS or PHA. mRNA expression of IL-18 and IL 18BP were 
      determined by quantitative real-time PCR using a comparative Ct (threshold cycle) 
      method. IL-18 levels in supernatants were measured by enzyme-linked immunosorbent 
      assay. Basal mRNA (4.5-fold) and protein levels of IL-18 were increased and 
      IL-18BP mRNA expression was decreased (8-fold) in RA patients when compared to 
      controls. Similarly, increased IL-18 levels were observed in active RA patients, 
      whereas IL-18BP expression was increased in inactive patients. There was an 
      increase in mRNA and protein levels of IL-18 in RA patients that peaked at 4 h 
      and 8 h respectively following LPS stimulation. A similar profile was observed 
      for IL-18BP; however, the expression level was higher in controls than RA 
      patients. Persistent high production of IL-18 in RA is associated with disease 
      progression and IL-18 BP seems to inhibit this activity.
FAU - Sivalingam, S P
AU  - Sivalingam SP
AD  - Department of Medicine, National University of Singapore, Republic of Singapore. 
      ssuppiah@dso.org.sg
FAU - Thumboo, J
AU  - Thumboo J
FAU - Vasoo, S
AU  - Vasoo S
FAU - Fong, K Y
AU  - Fong KY
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20070224
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Interleukin-18)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Phytohemagglutinins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptors, Interleukin-18)
RN  - 0 (interleukin-18 binding protein)
SB  - IM
MH  - Arthritis, Rheumatoid/blood/*genetics
MH  - Gene Expression Profiling
MH  - HLA-DR Antigens/*genetics/metabolism
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*genetics
MH  - Interleukin-18/*genetics
MH  - Leukocytes, Mononuclear/*physiology
MH  - Lipopolysaccharides/pharmacology
MH  - Phytohemagglutinins/pharmacology
MH  - *Polymorphism, Genetic
MH  - RNA, Messenger/drug effects/metabolism
MH  - Receptors, Interleukin-18/*genetics
EDAT- 2007/03/21 09:00
MHDA- 2007/06/26 09:00
CRDT- 2007/03/21 09:00
PHST- 2006/10/20 00:00 [received]
PHST- 2006/12/27 00:00 [revised]
PHST- 2007/02/16 00:00 [accepted]
PHST- 2007/03/21 09:00 [pubmed]
PHST- 2007/06/26 09:00 [medline]
PHST- 2007/03/21 09:00 [entrez]
AID - S0024-3205(07)00183-X [pii]
AID - 10.1016/j.lfs.2007.02.020 [doi]
PST - ppublish
SO  - Life Sci. 2007 Apr 24;80(20):1887-96. doi: 10.1016/j.lfs.2007.02.020. Epub 2007 
      Feb 24.